Seronegative myasthenia gravis. Subtypes and clinical manifestations
DOI:
https://doi.org/10.52692/1857-0011.2024.3-80.02Abstract
Approximately 10-15% of patients diagnosed with Myasthenia gravis do not have detectable antibodies in standard tests. This may be due to the presence of pathogenic antibodies against postsynaptic membrane antigens other than AChR, or the antibody levels may be below the detection limit. The discovery of low-affinity anti-AChR, anti-MuSk, ani-LRP4, anti-agrin, anti-cortactin antibodies represents a considerable advance in the understanding of the pathophysiology. In recent years, significant progress has been made in the development of antigen-specific therapies that specifically target immune cells or autoantibodies involved in the autoimmune response.
References
Cortés-Vicente, Elena, et al. “Clinical Characteristics of Patients with Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin.” JAMA Neurology, vol. 73, no. 9, 1 Sept. 2016, pp. 1099–1104.
Gilhus, Nils E. “Myasthenia Gravis.” New England Journal of Medicine, vol. 375.
Katarzyna Marta Zoltowska, et al. “Collagen Q – a Potential Target for Autoantibodies in Myasthenia Gravis.” Journal of the Neurological Sciences, vol. 348, no. 1-2, 1 Jan. 2015, pp. 241–244.
Oana Catar, et al. “Myasthénie Auto-Immune Séronégative.” M S-Medecine Sciences, vol. 33, 1 Nov. 2017, pp. 34–38.
Pevzner, Alexandra, et al. “Anti-LRP4 Autoantibodies in AChR- and MuSK-Antibody-Negative Myasthenia Gravis.” Journal of Neurology, vol. 259.
Rodrigues, Paula Raquel do Vale Pascoal, et al. “Triple-Seronegative Myasthenia Gravis: Clinical and Epidemiological Characteristics.” Arquivos de Neuro- Psiquiatria, vol. 82.
Stergiou, C., et al. “Titin Antibodies in “Seronegative” Myasthenia Gravis — a New Role for an Old Antigen.” Journal of Neuroimmunology, vol. 292, Mar. 2016, pp. 108–115.
Vinciguerra, Claudia, et al. “Diagnosis and Management of Seronegative Myasthenia Gravis: Lights and Shadows.” Brain Sciences, vol. 13, no. 9, 5 Sept. 2023, p. 1286.
Westerberg, Elisabet. Environmental Factors of Importance in Myasthenia Gravis Emphasis on Physical Activity. 27 Apr. 2018.
Zhang, Bin, et al. “Autoantibodies to Agrin in Myasthenia Gravis Patients.” PLoS ONE, vol. 9, no. 3, 14 Mar. 2014, p. e91816.
Zhao, Guang, et al. “Clinical Application of Clustered- AChR for the Detection of SNMG.” Scientific Reports, vol. 5.
Downloads
Published
License
Copyright (c) 2025 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
